Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.10 Mil Enterprise Value: 126.27 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 50/100

Lexicon Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 12, 2022 / 12:45PM GMT
Release Date Price: €4.1
Joey Stringer
Needham & Company - Analyst

Good morning, everyone. Thank you for joining the 21st Annual Needham Healthcare Conference. My name is Joey Stringer and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, Lexicon Pharmaceuticals. Joining us today from Lexicon is CMO Craig Granowitz and President and CFO Jeff Wade.

Following the presentation we'll have a brief Q&A session. So, for those of you joining on the webcast, if you want to ask a question please do so at any time. (Conference Instructions). With that we'll get started. I'll turn it over to Jeff for the presentation.

Jeff Wade
Lexicon Pharmaceuticals, Inc. - President & CFO

Thanks, Joey, and thanks to Needham for giving us the opportunity to share with you a bit about Lexicon and about a very important year for the company. Next slide. I will be making forward-looking statements that are subject to risks and uncertainties that are described in our SEC filings.

Next slide. So, today is an important

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot